506029652 04/24/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6076367

SUBMISSION TYPE:		NEW ASSIGNMENT						
NATURE OF CONVEYANCE:		ASSIGNMENT						
CONVEYING PARTY DA	TA							
		Name	Execution Date					
THERACHON HOLDING	i GMBH		11/29/2019					
RECEIVING PARTY DATA								
Name:	PFIZER INC.							
Street Address:	235 EAST 42ND STREET							
City:	NEW YORK	NEW YORK						
State/Country:	NEW YORK	NEW YORK						
Postal Code:	10017							
PROPERTY NUMBERS	Total: 8							
Property Type		Number						
Application Number:	1554	1993						
Application Number: 1679		3666						
Application Number:6235		9607						
Application Number:6246		7478						
Application Number: 15943		3436						
Application Number: 1641		7174						
Application Number:	6256	1140						
Application Number:	1664	9208						
Fax Number:	· · ·	646-8646 e-mail address first; if that is uns	waaaaful it will be cont					
		hat is unsuccessful, it will be sen						
Phone:		617-646-8000						
Email:		patents_RobertS@wolfgreenfield.com, landon.summers@wolfgreenfield.com						
Correspondent Name:		ROBERT N. SAHR						
Address Line 1:	WOL	WOLF, GREENFIELD & SACKS, P.C.						
Address Line 2:		600 ATLANTIC AVENUE						
Address Line 4:	BOST	ON, MASSACHUSETTS 02210						
ATTORNEY DOCKET NU	MBER:	P1139.90000US00						
NAME OF SUBMITTER:		ROBERT N. SAHR						

SIGNATURE:	/Robert N. Sahr/				
DATE SIGNED:	04/24/2020				
Total Attachments: 5					
source=P113990000US00-ASI-ROS #page1.tif					
source=P113990000US00-ASI-ROS #page2.tif					
source=P113990000US00-ASI-ROS #page3.tif					
source=P113990000US00-ASI-ROS #page4.tif					
source=P113990000US00-ASI-ROS #page5.tif					

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (the "Assignment") is made effective as of November 29, 2019 (the "Effective Date"), by and between Therachon Holding GmbH, a Swiss limited liability company organized under the laws of Switzerland, whose main office is located at Grosspeteranlage 29, 4052 Basel, Switzerland ("Assignor") and Pfizer Inc., a corporation organized according to the laws of the State of Delaware, United States of America, whose main office is located at 235 East 42nd Street, New York, New York 10017, United States of America ("Assignee"). Assignor and Assignee are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

RECITALS:

WHEREAS, Assignor and Assignee are parties to that certain ASSET TRANSFER AGREEMENT, dated as of <u>November 29, 2019</u> (the "<u>Asset Transfer Agreement</u>"); and

WHEREAS, pursuant to the Asset Transfer Agreement, Assignor has assigned to Assignee all of Assignor's right, title and interest in, to and under the patents and applications therefor identified on <u>Schedule A</u> hereto (collectively, the "<u>Assigned Patent Rights</u>");

NOW, THEREFORE, for good and valuable consideration the receipt of which is hereby acknowledged and in consideration of the mutual agreements, provisions and covenants contained in the Asset Transfer Agreement and this Assignment, the Parties, intending to be legally bound, hereby agree as follows:

- 1. Conveyance. Pursuant to Section [1.1] of the Asset Transfer Agreement, Assignor contributed, assigned, transferred, and conveyed to Assignee its entire right, title and interest in, to and under (a) the Assigned Patent Rights, for the United States and for all other countries, including any and all (i) divisionals, continuations, and continuations-in-part that claim priority to any Assigned Patent Rights to the extent the claims thereof are entirely supported by such Assigned Patent Rights, (ii) reissues, renewals, extensions, or additions of the Assigned Patent Rights, (iii) foreign equivalents of the Assigned Patent Rights, and (iv) rights to apply for, prosecute and obtain patents in respect of any of the inventions to the extent fully supported by the Assigned Patent Rights in any country of the world, including the right to claim priority from the Assigned Patent Rights under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements which afford similar priority-claiming privileges, in all countries of the world, (b) the right to sue for and to recover damages and other remedies in respect of any past, present or future infringement or other unauthorized use of the Assigned Patent Rights, and (c) any and all claims for financial compensation (including but not limited to damages) in connection with past infringements of any Assigned Patent Right.
- 2. <u>Issuance and Recordation</u>. Assignor hereby authorizes and requests the applicable governmental authority with jurisdiction over patents and any official of any country whose duty it is to issue patents on applications as described above, to issue any and all Assigned Patent Rights to Assignee, its successors and assigns, in accordance with the terms of this Assignment. Assignor hereby requests the applicable governmental authority with

jurisdiction over patents, and the corresponding entities or agencies in any applicable jurisdiction, to record Assignee as the assignee and owner of the Assigned Patent Rights. Assignee shall have the right to record this Assignment with all applicable government authorities and registrars so as to perfect its ownership of the Assigned Patent Rights.

- 3. <u>No Modification</u>. Nothing contained in this Assignment is intended to or shall be deemed to modify, alter, amend or otherwise change any of the rights or obligations of Assignee or Assignor under the Asset Transfer Agreement or any other agreement entered into by the Parties or any of their affiliates.
- 4. <u>Successors and Assigns</u>. This Assignment shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.
- 5. <u>Counterparts.</u> This Assignment may be executed in one or more counterparts, each of which shall be deemed an original, and all of which shall constitute one and the same assignment and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood that both parties need not sign the same counterpart.
- 6. <u>Interpretation</u>. The Article and Section headings contained in this Assignment are solely for the purpose of reference, are not part of the agreement of the Parties and shall not in any way affect the meaning or interpretation of this Assignment.
- 7. <u>Further Assurances</u>. Assignor and Assignee hereby covenant and agree, without the necessity of any further consideration, to execute, acknowledge, and deliver any and all such other documents and take any such other action as may be reasonably necessary or appropriate to implement this Assignment and carry out the intent and purposes of this Assignment.
- 8. <u>Governing Law</u>. This Assignment shall be governed by and construed and interpreted in accordance with the laws of New York, United States of America.
- 9. Jurisdiction. Any judicial proceeding brought by either of the Parties hereunder against the other with respect to this Assignment may be exclusively brought in the competent courts of New York, and, by its execution and delivery of this Assignment, Assignor (a) accepts, generally and unconditionally, the jurisdiction of such courts and irrevocably agrees to be bound by any judgment rendered thereby and (b) irrevocably waives any objection it may now or hereafter have as to the venue of any suit, action or proceeding brought in such a court or that such court is an inconvenient forum. Assignor consents that service of process upon it may be made by certified or registered mail, return receipt requested, at its address specified or determined above and service so made shall be deemed completed when received. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of Assignee to bring proceedings against Assignor in the courts of any other jurisdiction.

[Signature page follows]

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.

ASSIGNOR:

ASSIGNOR:

Therachon Holding GmbH

1 Yanny Vinnou Ti 4a 4 20 Maraging Director Name: Title:

Therachon Holding GmbH

Name: Calling Bruchingr

Title: Manapino D

IN WITNESS WHEREOF, Assignee has caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.

ASSIGNEE:

Pfizer Inc.

Name: Eric Agroman Title: Chief Cossiel IP + IPF

SCHEDULE A

Socket Number	Country	Application Number	Application	Status	Owner at PTO	3 39 0
046175A	Čanavia	2972885	Date 7Jan-18	Filed	Therachon Université Nice Scotia	Solutile Fort's Decoye For Treating Skeletal Growth
846179	European Patent Convension	⁹ 5290003 1	7.Jan-15	inactive	Antipolia/INSERM Theraction S48 /Université Nice Sophia	Disorders Soluble Fight Decays For Treating Skaletal Growth
0401734	European Patent Convention	467166735	7-130-16	Filog	Antipolis/NSERM Therachon SAS /Université Nice Stolia Antipolis/NSERM	Disorders Solide Fat3 Decoys For Treating Societal Countin
949173A	Hong Kong	90105647.6	7-Jan-16	Filed	Antipolizardoz nas Therachon/Universite Nice Sophia Antipolizarie/SERM	Disorders Soluble Fgft3 Decoys For Treating Sheletel Growth Disorders
546179A	Septen	2017-535917	7-Jan-16	Fist	Therachandunkersite Nice Southis Antipole INSERM	Counters Soluble Fight: Decoys For Treating: Siteletal Crowth Disorders
0403794	Patent Cooperation Treaty	PCT/82018/000403	7-385-16	mactive	NerachovUniversité Nice Sconia Antipolis/NSERM	Skitzberg Skitzbe Figtil Decoys For Treating Sheletal Growth Disorders
8483784	United States	15-54-1993	7-380-18	Filed	Therachen/Université Nice Socilie Antipolis/INSERBI	Solutive Fight Decoys For Treating Skeletal Growth Disorders
6401504	Australia	2017294551	7~64-17	Fied	Therachon SAS/Université Nice Sophia Antipolia/NSERM	Boliulio Fibrabiast Growth Factor Receptor 3 (StpH3) Polyceptides And Lises Thereof
0401884	Bairrain	BP 18/2919	7-ka-17	Filed	Therachon SAS/Université Nice Sophia Antipolis/NISERM	Schuble Filmotilast Growth Factor Receptor 3 (Bigh3) Potypeptides And Uses Thereof
649788A	Brazil		7-28-17	Filed	Therachon SAS/Université Nice Sophia Antipolis/NISERM	Soluble Febroblast Growth Factor Receptor 3 (Sign3) Polypeolides And Uses Therest
040130A	Canada	\$629677 	7-301-17	Filed	Therarchion SASA intervite Mirce Sophia Antipolic/WSERM	Solutile Fibrotlest Growth Faster Reseptor 3 (Sign3) Phlypaptides And Uses Thereof
8401984		201790049433.8 	7-36-17	Filed	Therachon SAS/Université Nice Sophia Antipolis/INSERM	Solutile Fibrosissi Growth Factor Receptor 3 (Sigir3) Polypeptides And Uses Thereof
040180A	European Patent Convention	17742195 5		Filed	Therachan SAS/Université Nice Scotia Antipolic/NISERS	Soluble Fibrobiast Growth Factor Receptor 3 (Sige3) Polypeptides And Uses Thereof
940186A	Israel	264930		Fled	Theraction SAS/Université Nace Sochia Antipolis/#ISERM	Soluble Fibroblast Growth Pactor Receptor 3 (36983) Polypeotides And Uses Thereof
040180A	saman	2019-500261		Filed	Therachon SAS/Université Nice Sophia Antipolis/NISERM	Soluble: Fibrobiast Growth Pactor Receptor 3 (Sigit3) Polyceptides: And Uses Thereaf
040196A	Korea Stoth	10-2019-7002602	7-315-17	Fied	Theraction BABA Intersité Nice Sophia Antipolis/NISERM	Soluble Fibrobleat Crowth Fector Receptor 5 (Sight) Polypeptides And Uses Thereof
6491864	Konnad	PCT/242/2018	7-101-17	Päed	Theraction SAS/Université Nice Scotia Antipolis/NSERM	Solidite Filosobiast Growth Factor Receptor 3 (Sigir3) Polypoptides And Uses Thereof
640186A	Maxico		7-shik-17	Flet	Theraction SAS/Université Nice Sophia Antipolis/INSERM	Soluble Filmblast Growth Pactor Receptor 3 (Sigh3) Polypeotides And Uses Thereof
(46180A	New Zesland	748918	7-201-17	Filed	Theraction SAS/Universitie Nice Sophia Antipolis/NSERM	Solutive Febroblast Growth Factor Receptor 3 (Sigh3) Polypeptides: And Uses Thereof
0401804	Ŭman	OM-P-2915/0009	7-Jul-17	Filed	Theraction SAS/Universite Nice Sophia - Antipolic/NISERM	Solutile Fibrotilest Growth Factor Receptor 3 (Sigh3) Polypeotides And Uses Thereof
04013804		PCT/EP2917/06711 3	2,44-17	inactive	Theraction SAS/Université Nice Scottig Antionalis/INSERSI	Soluble Fibrobizst Growth Factor Receptor 3 (Sign3) Polypaptides And Uses Thereof
946186A		QA/201901/050015	7 ~10 1-17	Filed	Theraction SASUminerate Nice Social Antipolic/NISERM	Solvible Filmoblast Growth Factor Receptor 3 (Stgir3) Polyceptides And Uses Thereof
546180A	Russian Federation	2019100381	7-88-17	Filed	Therachon SASK Inversité Nice Sophia Antipolis/NSERM	Soluble Filmblast Growth Factor Recentor 3 (Sigh3) Polypantides And Uses Thereof
0401980A	Sauci Arabia	\$19400915	7-388-17	Filed	Therachen SAS/Université Nice Sophia Antipolo/NISERM	Solutile Fibroslast Crowth Factor Receptor 3 (Sigh3) Polysophides: And Uses Thereof
9401504	Singapore	11201990074%	?~k&-3?	Filed	Therachon SASIUnkersité Nice Sophia Antipalis/NISERM	Solidble Fibroblast Growth Factor Receptor 3 (Stigh3) Polycepticles And Uses Thereof
940186A	South Affica	2015/00507	2-38-13	Filed	Theraction SAS/Université Nice Sociale Antipolic/INSERM	Solutive Fluoritiest Growth Factor Receptor 3 (Stat 3) Porycecptides And Uses Thoread
840188A	United Arst Emirates	P6000022/2013	7-24-17	Filed	Therachon SAS Université Nice Sophie Antipole NISERU	Solutie Pitrotiast Growth Factor Receptor 3 (Sigh3) Polycepitides And Uses Thereof
\$40180	United States	62/369607	7-361-16	hactive	and the start and and and the start and a start of the st	Solution Filmolitant Growth Factor Receptor 3 (Sigit)) Polyceptides: And Uses Thereof
\$40 180	United States	62467478	3~800-17	hactive		Solutive Fibroblass Growth Factor Receptor 3 (Sight)) Polyceptides And Uses Thereof
646186A	United States	15743438	7~64-57	Filed	Therachen SAS/Université Nice Sophia Antipolis/RISERM	Soluble Filmoidest Growth Factor Receptor 3 (Sight) Polycecilides And Uses Thereof
849381A	Patent Cooperation Treaty	PCT/EP2018/07547 1	20-Sep-18	Filed	Therachon SAS/Université Nice Sophia Antipolia MISERM/CNRS	Treatment Of Abnormal Viscenal Pat Deposition Using Soluble Finctiblest. Growth Pactor Receptor 3 (Stylf3) Polypeptides
\$40181	United States	82/581140	20-8ep 17 (inactive	Therachon SAS/Université Nice Sophia Antipolis INSERM/CNRS	Forgregations Treatment Of Athormal Visceral Fat Deptection Using Solutile Fibrotilest Growth Factor Receptor 3 (Start) Polypeotides